Literature DB >> 20955970

Alcoholic steatohepatitis.

Felix Stickel1, Helmut K Seitz.   

Abstract

Severe alcoholic steatohepatitis has a poor prognosis and is characterized by jaundice and signs of liver failure. Its incidence is unknown, but prevalence is around 20% in cohorts of alcoholics undergoing liver biopsy. Diagnosis is established with elevated liver transaminases, neutrophil counts, serum bilirubin, and impaired coagulation and a history of excessive alcohol consumption, and exclusion of other etiologies. Histology is helpful but not mandatory. Prognostic scores include the Maddrey's discriminant function, the model of end-stage liver disease, and the Glasgow Alcoholic Hepatitis Score. Pathophysiology involves hepatic fat storage, increased hepatic uptake of gut-derived endotoxins triggering Kupffer cell activation and release of proinflammatory triggers, induction of cytochrome P4502E1 producing toxic acetaldehyde and reactive oxygen species, and ethanol-mediated hyperhomocysteinemia causing endoplasmic reticulum stress. Treatment includes abstinence, enteral nutrition, corticosteroids, and possibly pentoxifylline. A debate is ongoing whether certain patients with severe alcoholic steatohepatitis could be eligible for liver transplantation.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20955970     DOI: 10.1016/j.bpg.2010.07.003

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  20 in total

1.  Schisandra chinensis prevents alcohol-induced fatty liver disease in rats.

Authors:  Hyoung Joon Park; Soo-Jung Lee; Yuno Song; Sun-Hee Jang; Yeoung-Gyu Ko; Suk Nam Kang; Byung Yeoup Chung; Hong-Duck Kim; Gon-Sup Kim; Jae-Hyeon Cho
Journal:  J Med Food       Date:  2014-01       Impact factor: 2.786

Review 2.  Antiretroviral Therapy and Alcohol Interactions: X-raying Testicular and Seminal Parameters Under the HAART Era.

Authors:  Oluwatosin O Ogedengbe; Edwin C S Naidu; Onyemaechi O Azu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-04       Impact factor: 2.441

3.  Alcohol steatosis and cytotoxicity: the role of cytochrome P4502E1 and autophagy.

Authors:  Defeng Wu; Xiaodong Wang; Richard Zhou; Lili Yang; Arthur I Cederbaum
Journal:  Free Radic Biol Med       Date:  2012-07-20       Impact factor: 7.376

Review 4.  Alcoholic liver disease: pathogenesis and new therapeutic targets.

Authors:  Bin Gao; Ramon Bataller
Journal:  Gastroenterology       Date:  2011-09-12       Impact factor: 22.682

5.  Pentoxifylline aggravates fatty liver in obese and diabetic ob/ob mice by increasing intestinal glucose absorption and activating hepatic lipogenesis.

Authors:  J Massart; M A Robin; F Noury; A Fautrel; P Lettéron; A Bado; P A Eliat; B Fromenty
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

6.  Pentoxifylline for steatohepatitis: magic bullet or smoking gun?

Authors:  Richard K Sterling; Arun J Sanyal
Journal:  Hepatology       Date:  2011-11       Impact factor: 17.425

Review 7.  Chronic alcohol consumption potentiates the development of diabetes through pancreatic β-cell dysfunction.

Authors:  Ji Yeon Kim; Dae Yeon Lee; Yoo Jeong Lee; Keon Jae Park; Kyu Hee Kim; Jae Woo Kim; Won-Ho Kim
Journal:  World J Biol Chem       Date:  2015-02-26

8.  Mouse model of chronic and binge ethanol feeding (the NIAAA model).

Authors:  Adeline Bertola; Stephanie Mathews; Sung Hwan Ki; Hua Wang; Bin Gao
Journal:  Nat Protoc       Date:  2013-02-28       Impact factor: 13.491

Review 9.  Focus on alcoholic liver disease: from nosography to treatment.

Authors:  Letiția Adela Maria Streba; Cristin Constantin Vere; Costin Teodor Streba; Marius Eugen Ciurea
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

10.  CYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis, and apoptosis.

Authors:  Mohamed A Abdelmegeed; Atrayee Banerjee; Sehwan Jang; Seong-Ho Yoo; Jun-Won Yun; Frank J Gonzalez; Ali Keshavarzian; Byoung-Joon Song
Journal:  Free Radic Biol Med       Date:  2013-09-21       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.